Editas Medicine Inc (EDIT)

Editas Medicine Inc (EDIT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $445M; returns 1 day -3.6%, 1 week +2.1%, 1 year -34.2%.

Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat a range of serious diseases using CRISPR technology. The company's strategy is now heavily focused on in vivo gene editing, particularly with its lead candidate EDIT-401.

Groups EDIT belongs to

• Biotechnology
• Clinical Stage Biotech
• Gene Therapy
• Life Sciences
• Healthcare
• Precision Medicine
• Rare Diseases
• Biopharmaceutical
• Hematology

EDIT financial model: income statement, cash flow and balance sheet